UOC
RGLS

UBS O'Connor’s Regulus Therapeutics RGLS Stock Holding History

UBS O'Connor’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-667
Closed -$1.28M – 829
2014
Q4 		$1.28M Buy
+667
New +$1.19M 0.02% 329
2014
Q2 		– Sell
-167
Closed -$180K – 525
2014
Q1 		$180K Sell
167
-36
-18% -$39.9K ﹤0.01% 401
2013
Q4 		$180K Buy
203
+9
+5% +$7.75K ﹤0.01% 346
2013
Q3 		$220K Buy
+194
New +$229K ﹤0.01% 352

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's RGLS Position: Q1 2015 in Review

UBS O'Connor sold out of Regulus Therapeutics (RGLS) in Q1 2015, closing a stake of 667 shares — an estimated $1.28M sold.

UBS O'Connor first reported a position in RGLS in Q3 2013 and held it in 4 quarters. The position peaked at $1.28M in Q4 2014. 88 funds tracked by Wall St. Rank hold RGLS as of Q1 2015.

  • UBS O'Connor reported no remaining Regulus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • UBS O'Connor sold 667 Regulus Therapeutics shares in Q1 2015, an estimated $1.28M.
  • UBS O'Connor first reported a position in Regulus Therapeutics in Q3 2013 and held it in 4 quarters.
  • UBS O'Connor's Regulus Therapeutics position peaked at $1.28M in Q4 2014.
  • 88 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2015.

Based on UBS O'Connor's 13F filing for Q1 2015, filed 14 May 2015.